Hemogenyx Pharmaceuticals PLC Announces Result of Audit Tender
Hemogenyx Pharmaceuticals (LSE: HEMO) has announced its decision to re-appoint PKF Littlejohn LLP as its external auditor for the financial year ending December 2025 and beyond. The decision follows a mandatory audit tender process required for public interest entities every ten years. The appointment will coincide with the mandatory lead audit partner rotation and requires shareholder approval at the company's 2026 Annual General Meeting.
The clinical-stage biopharmaceutical company, headquartered in London with US subsidiaries in New York City, focuses on developing treatments for blood and autoimmune diseases. The audit tender process was overseen by the Audit Committee, with detailed evaluation criteria to be disclosed in the Group's 2025 Annual Report & Accounts.
Hemogenyx Pharmaceuticals (LSE: HEMO) ha annunciato la decisione di riconfermare PKF Littlejohn LLP come revisore esterno per l'esercizio chiuso a dicembre 2025 e per gli anni successivi. La scelta segue la procedura obbligatoria di gara per le societ脿 di interesse pubblico, prevista ogni dieci anni. La nomina coincider脿 con la rotazione obbligatoria del partner responsabile della revisione e dovr脿 essere approvata dagli azionisti nell'Assemblea Generale 2026.
La societ脿 biofarmaceutica in fase clinica, con sede a Londra e filiali negli Stati Uniti a New York, 猫 focalizzata sullo sviluppo di terapie per malattie del sangue e autoimmuni. La gara di revisione 猫 stata supervisionata dal Comitato per la Revisione, e i criteri di valutazione dettagliati saranno pubblicati nel Bilancio Annuale del Gruppo 2025.
Hemogenyx Pharmaceuticals (LSE: HEMO) ha anunciado su decisi贸n de volver a nombrar a PKF Littlejohn LLP como auditor externo para el ejercicio que termina en diciembre de 2025 y los a帽os siguientes. La decisi贸n se produce tras un concurso de auditor铆a obligatorio para entidades de inter茅s p煤blico, que se realiza cada diez a帽os. El nombramiento coincidir谩 con la rotaci贸n obligatoria del socio principal de auditor铆a y requerir谩 la aprobaci贸n de los accionistas en la Junta General de 2026.
La compa帽铆a biofarmac茅utica en fase cl铆nica, con sede en Londres y filiales en Estados Unidos en Nueva York, se centra en desarrollar tratamientos para enfermedades sangu铆neas y autoinmunes. El proceso de concurso fue supervisado por el Comit茅 de Auditor铆a, y los criterios de evaluaci贸n detallados se incluir谩n en las Cuentas Anuales del Grupo de 2025.
Hemogenyx Pharmaceuticals (LSE: HEMO)電� 2025雲� 12鞗旊 雭濍倶電� 須岅硠鞐半弰 氚� 攴� 鞚错泟鞐� 雽�頃� 鞕鸽秬 臧愳偓鞚胳溂搿� PKF Littlejohn LLP毳� 鞛劆鞛勴晿旮半 瓴办爼頄堧嫟瓿� 氚滍憸頄堨姷雼堧嫟. 鞚� 瓴办爼鞚� 瓿店车鞝� 甏�鞁偓鞐� 頃措嫻頃橂姅 旮办梾鞐� 雽�頃� 10雲勲雼� 鞖旉惮霅橂姅 鞚橂鞝� 臧愳偓 鞛呾鞍 鞝堨皑鞐� 霐半ジ 瓴冹瀰雼堧嫟. 鞚措矆 靹犾瀯鞚� 欤缄皭靷� 韺岉姼雱堨潣 鞚橂鞝� 甑愳泊鞕� 霃欖嫓鞐� 鞚措（鞏挫氅�, 2026雲� 鞐半欤检＜齑濏殞鞐愳劀 欤检＜ 鞀轨澑鞚� 頃勳殧頃╇媹雼�.
霟半崢鞐� 氤胳偓毳� 霊愱碃 雺挫殨鞐� 氙戈淡 鞛愴殞靷ゼ 霊� 鞛勳儊 雼硠鞚� 氚旍澊鞓れ牅鞎� 須岇偓鞚� 鞚� 旮办梾鞚� 順堨暋 氚� 鞛愱皜氅挫棴 歆堩櫂 旃橂鞝� 臧滊皽鞐� 欤茧牓頃橁碃 鞛堨姷雼堧嫟. 臧愳偓 鞛呾鞍 鞝堨皑電� 臧愳偓鞙勳洂須岅皜 臧愲弲頄堨溂氅�, 靸侅劯頃� 韽夑皜 旮办鞚� 攴鸽９鞚� 2025雲� 鞐半 鞛氤搓碃靹滌棎 瓿店皽霅� 鞓堨爼鞛呺媹雼�.
Hemogenyx Pharmaceuticals (LSE: HEMO) a annonc茅 sa d茅cision de reconduire PKF Littlejohn LLP en tant qu'auditeur externe pour l'exercice clos en d茅cembre 2025 et au-del脿. Cette d茅cision fait suite 脿 une proc茅dure d'appel d'offres obligatoire pour les entit茅s d'int茅r锚t public, r茅alis茅e tous les dix ans. Cette nomination co茂ncidera avec la rotation obligatoire du partenaire principal d'audit et devra 锚tre approuv茅e par les actionnaires lors de l'assembl茅e g茅n茅rale 2026.
La soci茅t茅 biopharmaceutique en phase clinique, dont le si猫ge est 脿 Londres et qui poss猫de des filiales aux 脡tats-Unis 脿 New York, se concentre sur le d茅veloppement de traitements pour les maladies du sang et auto-immunes. La proc茅dure d'appel d'offres a 茅t茅 supervis茅e par le comit茅 d'audit ; les crit猫res d'茅valuation d茅taill茅s seront publi茅s dans les comptes annuels du groupe 2025.
Hemogenyx Pharmaceuticals (LSE: HEMO) hat beschlossen, PKF Littlejohn LLP als externen Abschlusspr眉fer f眉r das am Dezember 2025 endende Gesch盲ftsjahr und dar眉ber hinaus erneut zu bestellen. Die Entscheidung folgt auf ein verpflichtendes Ausschreibungsverfahren f眉r Pr眉fungen bei Unternehmen von 枚ffentlichem Interesse, das alle zehn Jahre durchzuf眉hren ist. Die Bestellung f盲llt mit der verpflichtenden Rotation des leitenden Pr眉fungspartners zusammen und bedarf der Zustimmung der Aktion盲re auf der Hauptversammlung 2026.
Das klinisch orientierte Biopharmaunternehmen mit Sitz in London und US-Niederlassungen in New York konzentriert sich auf die Entwicklung von Therapien f眉r Blut- und Autoimmunerkrankungen. Das Ausschreibungsverfahren wurde vom Pr眉fungsausschuss 眉berwacht; die detaillierten Bewertungskriterien werden im Jahresabschlussbericht der Gruppe 2025 ver枚ffentlicht.
- None.
- None.
LONDON, UK / / August 29, 2025 / Hemogenyx Pharmaceuticals plc (LSE: HEMO), is pleased to announce that following the conclusion of the formal tender process for the role of statutory auditor, it intends to re-appoint PKF Littlejohn LLP as external auditor for the financial year ending December 2025 onwards. This will coincide with the timing of the mandatory lead audit partner rotation.
The audit tender was conducted as a result of the requirement for public interest entities to undertake an audit tender at least every ten years. A thorough tender process, overseen by the Audit Committee, was undertaken and this proposed change of auditor follows a recommendation by the Audit Committee to the Board based on the outcome of the tender process.
Further details of the audit tender process and evaluation criteria will be included in the Group's 2025 Annual Report & Accounts. The appointment will be subject to shareholder approval at the Company's 2026 Annual General Meeting.
Enquiries:
Hemogenyx Pharmaceuticals plc | |
Dr Vladislav Sandler, Chief Executive Officer & Co-Founder | |
Peter Redmond, Director | |
SP Angel Corporate Finance LLP | Tel: +44 (0)20 3470 0470 |
Matthew Johnson, Vadim Alexandre, Adam Cowl | |
Peterhouse Capital Limited | Tel: +44 (0)20 7469 0930 |
Lucy Williams, Duncan Vasey, Charles Goodfellow | |
About Hemogenyx Pharmaceuticals plc
Hemogenyx Pharmaceuticals is a publicly traded company (LSE:HEMO) headquartered in London, with its US operating subsidiaries, Hemogenyx Pharmaceuticals LLC and Immugenyx LLC, located in New York City.
The Company is a clinical-stage biopharmaceutical group developing new medicines and treatments to treat blood and autoimmune diseases. Hemogenyx Pharmaceuticals is developing several distinct and complementary product candidates, as well as platform technologies that it uses as engines for novel product development.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit .
SOURCE: Hemogenyx Pharmaceuticals PLC
View the original on ACCESS Newswire
FAQ
When will PKF Littlejohn LLP begin their role as Hemogenyx Pharmaceuticals' (HOPHF) external auditor?
Why did Hemogenyx Pharmaceuticals (HOPHF) conduct an audit tender process?
What does Hemogenyx Pharmaceuticals (HOPHF) specialize in?
Where will shareholders find details about the audit tender process?
